Anti-VEGF therapy for retinal vein occlusions

C Campa, G Alivernini, E Bolletta… - Current drug …, 2016 - ingentaconnect.com
Retinal vein occlusion (RVO) is the second most common cause of visual loss in the
Western World. RVO is usually classified into branch RVO (BRVO) and central RVO (CRVO) …
被引用次数：107 相关文章

Anti-VEGF Therapy for Retinal Vein Occlusions

C Campa, G Alivernini, E Bolletta… - Current drug …, 2016 - pubmed.ncbi.nlm.nih.gov
Retinal vein occlusion (RVO) is the second most common cause of visual loss in the
Western World. RVO is usually classified into branch RVO (BRVO) and central RVO (CRVO) …

Anti-VEGF Therapy for Retinal Vein Occlusions

C Campa, G Alivernini, E Bolletta… - CURRENT DRUG …, 2017 - sfera.unife.it
Retinal vein occlusion (RVO) is the second most common cause of visual loss in the
Western World. RVO is usually classified into branch RVO (BRVO) and central RVO (CRVO) …

[引用][C] Anti-VEGF Therapy for Retinal Vein Occlusions

C Campa, G Alivernini, E Bolletta, MB Parodi… - Current Drug …, 2016 - cir.nii.ac.jp

Anti-VEGF Therapy for Retinal Vein Occlusions

C Campa, G Alivernini, E Bolletta, MB Parodi… - CURRENT DRUG …, 2016 - iris.unisr.it
Retinal vein occlusion (RVO) is the second most common cause of visual loss in the
Western World. RVO is usually classified into branch RVO (BRVO) and central RVO (CRVO) …

Anti-VEGF Therapy for Retinal Vein Occlusions.

C Campa, G Alivernini, E Bolletta, MB Parodi… - Current Drug …, 2016 - europepmc.org
Retinal vein occlusion (RVO) is the second most common cause of visual loss in the
Western World. RVO is usually classified into branch RVO (BRVO) and central RVO (CRVO) …